Novo Integrated Sciences, Inc.
NVOS · OTC
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.02 | -0.03 |
| FCF Yield | -9.15% | -3.36% | -15.39% | -10.72% |
| EV / EBITDA | 1.36 | -2.24 | -17.12 | -8.04 |
| Quality | ||||
| ROIC | -4.52% | -16.20% | -5.38% | -11.32% |
| Gross Margin | 51.21% | 28.46% | 41.76% | 49.96% |
| Cash Conversion Ratio | -0.11 | 0.05 | 0.62 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.24% | -15.72% | 7.14% | 8.15% |
| Free Cash Flow Growth | 16.82% | 61.49% | 20.39% | -730.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.53 | -0.29 | -5.08 | -1.05 |
| Interest Coverage | -0.56 | -0.82 | -1.23 | -2.72 |
| Efficiency | ||||
| Inventory Turnover | 1.50 | 2.03 | 1.95 | 1.53 |
| Cash Conversion Cycle | -41.73 | -46.77 | 1.37 | -37.61 |